LungLifeAI Logo

Lung Life AI's CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic, Lung LB®

June 25, 2024

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement and compliance with the US FDA Lab Developed Test ruling.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.